SIREN : 499681419
BIOFELY is a French company founded 18 years ago, specialized in the sector Production d'électricité. Based in REIMS (51100), this company of category GE shows in 2024 a revenue of 31.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31 493 511 € | 31 817 931 € | 30 228 363 € | 26 650 445 € | 28 024 007 € | 27 980 966 € | 25 336 140 € | 24 910 506 € | 24 410 995 € |
| Net income | 1 454 380 € | 2 479 521 € | 1 789 208 € | 2 955 431 € | 2 211 033 € | 3 158 476 € | -3 359 285 € | 1 488 799 € | 421 988 € |
| EBITDA | 6 090 927 € | 6 205 010 € | 5 929 186 € | 7 565 910 € | 7 142 073 € | 8 641 316 € | 6 847 556 € | 7 264 778 € | 5 821 377 € |
| Net margin | 4.6% | 7.8% | 5.9% | 11.1% | 7.9% | 11.3% | -13.3% | 6.0% | 1.7% |
In 2024, BIOFELY achieves revenue of 31.5 M€. Revenue is growing positively over 9 years (CAGR: +3.2%). Slight decline of -1% vs 2023. After deducting consumption (15.9 M€), gross margin stands at 15.6 M€, i.e. a rate of 50%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 6.1 M€, representing 19.3% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.5 M€, i.e. 4.6% of revenue. This profit can be retained or distributed to shareholders.
31 493 511 €
15 617 236 €
6 090 927 €
797 489 €
1 454 380 €
19.3%
The debt ratio (= Financial debt / Equity x 100) stands at 57%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 17.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
56.943%
41.717%
17.277%
2.706
47.0%
In 2024, the debt ratio of BIOFELY (56.94) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIOFELY (41.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of BIOFELY (2.71) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 93.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 8.6x. Operating income very largely covers interest expenses: high safety margin.
93.27
8.646
In 2024, the liquidity ratio of BIOFELY (93.27) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of BIOFELY (8.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 90 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 124 days. Excellent situation: suppliers finance 34 days of the operating cycle (retail model). Inventory turnover is 8 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 67 days of revenue, i.e. 5.9 M€ to permanently finance. Over 2016-2024, WCR increased by +1887%, requiring additional financing.
5 884 877 €
90 j
124 j
8 j
67 j
Based on 85 transactions of similar company sales
(all years),
the value of BIOFELY is estimated at
14 743 181 €
(range 2 308 174€ - 63 910 417€).
With an EBITDA of 6 090 927€, the sector multiple of 2.4x is applied.
The price/revenue ratio is 0.69x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOFELY with other companies in the same sector:
Voir toutes les statistiques du secteur Production d'électricité
The revenue of BIOFELY in 2024 is 31.5 M€.
Yes, BIOFELY generated a net profit of 1.5 M€ in 2024.
The headquarters of BIOFELY is located in REIMS (51100), in the department Marne.
The tax return of BIOFELY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOFELY operates in the sector Production d'électricité (NAF code 35.11Z). See the 'Sector positioning' section above to compare the company with its competitors.